STOCK TITAN

MiMedx Group (MDXG) Financials

MDXG NASDAQ
Trailing 12 months to September 30, 2026
Revenue $303.7M -22.8% YoY
Net Income -$19.2M -147.0% YoY
EPS (Diluted) -$0.13 -148.1% YoY
Operating Cash Flow $20.7M -69.4% YoY
Market Cap $445.1M as of Nov 20, 2026
Price / Sales 1.5x on $303.7M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 2.1x on $211.1M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Oct 28, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MDXG SEC filings page.

MiMedx Group, Inc (MDXG) reported $303.7M in revenue over the twelve months to Sep 30, 2026, down 22.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MDXG FY2025

MiMedx is scaling profitably, but its latest growth produced less incremental operating profit while receivables expanded faster than sales.

The business gained efficiency between FY2023 and FY2025: revenue increased 30.2% while operating income increased 72.1%. In FY2025, however, revenue grew 20.0% while operating income grew 8.5%, so the latest expansion produced less incremental operating profit than the preceding two-year stretch.

Operating cash flow reached $74.0M against net income of $48.6M, showing reported profit translated into more cash than earnings alone. The 152.3% cash-to-profit ratio is favorable, but receivables grew faster than revenue in FY2025, making working-capital collection an important part of the cash result.

Debt-to-equity fell from 0.3x in FY2023 to 0.1x in FY2025, reducing reliance on borrowing as the balance sheet expanded. Liabilities were 25.1% of assets in FY2025, while the current ratio was 4.3x, giving the reported structure substantial short-term asset coverage.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 74 / 100
Financial Health Score 74/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of MiMedx Group, Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
60

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. MiMedx Group, Inc scores 60/100 on it among other operating companies.

Growth
73

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. MiMedx Group, Inc scores 73/100 on it among other operating companies.

Leverage
94

MiMedx Group, Inc held more cash than long-term debt at the end of fiscal year 2025, with $166.1M of cash against $16.5M of long-term debt. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and MiMedx Group, Inc scores 94/100 among other operating companies measured the same way.

Liquidity
89

MiMedx Group, Inc held $4.32 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 4.32. Liquidity ranks operating companies on that ratio, and MiMedx Group, Inc scores 89/100 among other operating companies.

Cash Flow
58

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. MiMedx Group, Inc scores 58/100 on it among other operating companies.

Returns
71

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. MiMedx Group, Inc scores 71/100 on it among other operating companies.

Altman Z-Score Safe
5.51

MiMedx Group, Inc scores 5.51, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $445.1M against total liabilities of $86.1M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral
5/9

MiMedx Group, Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed
1.52x

For every $1 of reported earnings, MiMedx Group, Inc generates $1.52 in operating cash flow ($74.0M OCF vs $48.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe
35.83x

MiMedx Group, Inc earns $35.83 in operating income for every $1 of interest expense ($63.9M vs $1.8M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$62.3M
YoY-45.2%
QoQ-3.2%
5Y CAGR-0.3%
10Y CAGR-0.3%

MiMedx Group, Inc generated $62.3M in revenue in Q3 2026. This represents a decrease of 45.2% from the same quarter a year earlier. Against the prior quarter it is down 3.2%.

EBITDA
-$11.0M
YoY-148.3%
QoQn/m

MiMedx Group, Inc's EBITDA was -$11.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 148.3% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$8.7M
YoY-151.8%
QoQn/m
5Y CAGRn/m

MiMedx Group, Inc reported a net loss of $8.7M in Q3 2026. This represents a decrease of 151.8% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.06
YoY-154.5%
QoQn/m

MiMedx Group, Inc earned -$0.06 per diluted share (EPS) in Q3 2026. This represents a decrease of 154.5% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Cash & Debt
$120.8M
YoY-15.0%
QoQ-11.1%
5Y CAGR+5.9%
10Y CAGR+20.7%

MiMedx Group, Inc held $120.8M in cash against $0 in long-term debt as of Q3 2026.

Shares Outstanding
146M
YoY-1.5%
QoQ+0.1%

MiMedx Group, Inc had 146M shares outstanding in Q3 2026. This represents a decrease of 1.5% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
79.8%
YoY-3.7pp
QoQ+10.8pp
5Y change-4.1pp
10Y change-7.8pp

MiMedx Group, Inc's gross margin was 79.8% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 3.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.8 percentage points.

Operating Margin
-18.8%
YoY-38.3pp
QoQ+9.9pp
5Y change-17.1pp

MiMedx Group, Inc's operating margin was -18.8% in Q3 2026, reflecting core business profitability. This is down 38.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 9.9 percentage points.

Net Margin
-13.9%
YoY-28.7pp
QoQ+9.1pp
5Y change-10.2pp
10Y change-19.1pp

MiMedx Group, Inc's net profit margin was -13.9% in Q3 2026, showing the share of revenue converted to profit. This is down 28.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 9.1 percentage points.

Return on Equity
-4.1%
YoY-11.1pp
QoQ+2.8pp

MiMedx Group, Inc's quarterly ROE was -4.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 11.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.8 percentage points.

Capital Allocation

R&D Spending
$2.8M
YoY-24.5%
QoQ+0.7%
5Y CAGR-8.5%

MiMedx Group, Inc invested $2.8M in research and development in Q3 2026. This represents a decrease of 24.5% from the same quarter a year earlier. Against the prior quarter it is up 0.7%.

Share Buybacks
$304K
YoYn/m

MiMedx Group, Inc spent $304K on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Capital Expenditures

Not reported for Q3 2026.

MDXG Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MDXG quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$62.3M-45.2%$64.4M-34.7%$59.0M-33.1%$118.1M+27.1%$113.7M+35.3%$98.6M+13.1%$88.2M+4.1%$92.9M+7.0%
Cost of Revenue$12.6M-32.8%$20.0M+7.0%$17.4M+4.9%$19.1M+12.7%$18.7M+22.2%$18.7M+25.8%$16.6M+27.5%$16.9M+22.2%
Gross Profit$49.7M-47.7%$44.4M-44.5%$41.6M-41.9%$99.0M+30.3%$95.0M+38.2%$79.9M+10.5%$71.6M-0.1%$76.0M+4.1%
R&D Expenses$2.8M-24.5%$2.8M-15.9%$4.1M+24.4%$4.8M+33.4%$3.7M+26.9%$3.3M+9.7%$3.3M+17.1%$3.6M+46.7%
SG&A Expenses$58.3M-15.5%$59.8M-6.8%$53.2M-11.2%$73.1M+19.7%$69.0M+28.9%$64.2M+15.8%$60.0M+8.8%$61.0M+12.3%
Operating Income-$11.7M-152.7%-$18.5M-249.3%-$16.0M-294.5%$21.1M+90.6%$22.2M+98.8%$12.4M-47.2%$8.3M-37.5%$11.1M-28.6%
EBITDA-$11.0M-148.3%-$17.7M-236.1%-$15.2M-270.9%$21.8M+84.4%$22.9M+91.7%$13.0M-46.2%$8.9M-36.1%$11.8M-27.5%
Interest ExpenseN/AN/A$402K-15.9%$405K-22.3%$425K-18.4%$475K-9.0%$478K-79.9%$521K
Income Tax-$2.4M-139.0%-$2.9M-186.8%-$4.5M-381.4%$6.6M+73.3%$6.1M+72.3%$3.4M-39.4%$1.6M-32.3%$3.8Mn/m
Net Income-$8.7M-151.8%-$14.8M-254.3%-$10.9M-254.6%$15.2M+104.2%$16.7M+106.9%$9.6M-45.4%$7.0M-24.2%$7.4M-86.1%
EPS (Basic)-$0.06-154.5%-$0.10-242.9%-$0.07-240.0%$0.10+100.0%$0.11+120.0%$0.07-41.7%$0.05-16.7%$0.05-87.5%
EPS (Diluted)-$0.06-154.5%-$0.10-266.7%-$0.07-240.0%$0.10+100.0%$0.11+120.0%$0.06-50.0%$0.05-16.7%$0.05-86.5%
Diluted Shares (Avg)146M-2.6%148M-1.0%148M-0.8%N/A150M+0.9%149M+0.3%150M-0.2%N/A

MDXG Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MDXG quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$264.6M-17.1%$281.0M-3.5%$308.7M+14.1%$342.7M+29.8%$319.0M+30.8%$291.1M+26.5%$270.4M+22.0%$263.9M+10.4%
Current Assets$187.2M-26.3%$205.4M-7.0%$240.3M+20.1%$277.5M+44.6%$254.1M+47.6%$220.9M+43.4%$200.1M+44.1%$191.9M+16.8%
Cash & Equivalents$120.8M-15.0%$135.8M+14.3%$159.8M+50.1%$166.1M+59.1%$142.1M+60.0%$118.9M+72.2%$106.4M+119.5%$104.4M+27.3%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Inventory$22.1M-16.7%$20.9M-15.9%$26.2M+9.0%$25.3M+6.4%$26.5M+9.3%$24.9M-0.7%$24.1M-1.6%$23.8M+13.3%
Accounts Receivable$37.3M-52.3%$41.3M-40.3%$46.0M-26.1%$75.7M+35.6%$78.2M+44.7%$69.2M+31.1%$62.3M+9.2%$55.8M+3.6%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$19.4M0.0%$19.4M0.0%$19.4M0.0%$19.4M0.0%$19.4M0.0%$19.4M0.0%$19.4M0.0%$19.4M0.0%
Total Liabilities$53.5M-33.2%$65.0M-12.7%$65.7M-2.8%$86.1M+21.6%$80.0M+27.3%$74.5M+19.9%$67.6M+2.6%$70.8M-26.5%
Current Liabilities$43.0M-25.4%$38.5M-23.4%$44.5M+4.5%$64.3M+40.9%$57.7M+37.5%$50.3M+25.7%$42.6M+0.9%$45.6M-0.9%
Non-Current Liabilities$10.4M-53.3%$26.5M+9.5%$21.2M-15.3%$21.8M-13.4%$22.4M+6.8%$24.2M+9.3%$25.0M+5.5%$25.2M-49.9%
Long-Term Debt$0-100.0%$15.7M-8.7%$16.1M-8.2%$16.5M-7.6%$16.8M-6.5%$17.2M-5.7%$17.5M-5.0%$17.8M-62.9%
Total Equity$211.1M-11.7%$216.0M-0.3%$242.9M+19.8%$256.5M+32.9%$238.9M+32.0%$216.6M+28.9%$202.8M+30.2%$193.1M+35.3%
Retained Earnings-$77.1Mn/m-$68.4Mn/m-$53.5Mn/m-$42.7Mn/m-$57.9Mn/m-$74.6Mn/m-$84.2Mn/m-$91.3Mn/m

MDXG Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MDXG quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$3.9M-86.6%-$10.0M-169.5%$1.9M-64.5%$25.0M+32.9%$29.3M+49.5%$14.4M-33.9%$5.3M-11.4%$18.8M+83.1%
Depreciation & Amortization$665K-2.8%$732K+11.2%$829K+26.2%$701K-7.4%$684K-11.4%$658K-12.0%$657K-12.0%$757K-5.7%
Stock-Based CompensationN/AN/A-$1.7M-139.8%N/AN/AN/A$4.3M-1.8%N/A
Investing Cash Flow-$193Kn/m-$635Kn/m-$5.6Mn/m-$335Kn/m-$5.3M-4753.1%-$887Kn/m-$406Kn/m-$2.8Mn/m
Financing Cash Flow-$18.8Mn/m-$13.3Mn/m-$2.6Mn/m-$583Kn/m-$857K-3274.1%-$1.1Mn/m-$2.9Mn/m-$400Kn/m
Share Buybacks$304Kn/mN/AN/A$0$0N/AN/AN/A

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.

MDXG Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MDXG quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin79.8%-3.7pp69.0%-12.1pp70.6%-10.7pp83.9%+2.1pp83.5%+1.8pp81.0%-1.9pp81.2%-3.4pp81.8%-2.3pp
Operating Margin-18.8%-38.3pp-28.7%-41.2pp-27.2%-36.6pp17.8%+5.9pp19.5%+6.2pp12.6%-14.3pp9.3%-6.2pp11.9%-5.9pp
Net Margin-13.9%-28.7pp-23.1%-32.8pp-18.4%-26.4pp12.9%+4.8pp14.7%+5.1pp9.8%-10.5pp8.0%-3.0pp8.0%-53.6pp
Return on Equity-4.1%-11.1pp-6.9%-11.3pp-4.5%-7.9pp5.9%+2.1pp7.0%+2.5pp4.4%-6.0pp3.5%-2.5pp3.9%-33.6pp
Return on Assets-3.3%-8.5pp-5.3%-8.6pp-3.5%-6.1pp4.4%+1.6pp5.3%+1.9pp3.3%-4.4pp2.6%-1.6pp2.8%-19.6pp
Current Ratio4.35-0.1x5.33+0.9x5.39+0.7x4.32+0.1x4.41+0.3x4.39+0.5x4.70+1.4x4.21+0.6x
Debt-to-Equity0.00-0.1x0.070.0x0.070.0x0.060.0x0.070.0x0.080.0x0.090.0x0.09-0.2x
Liabilities-to-Equity0.25-0.1x0.300.0x0.27-0.1x0.340.0x0.340.0x0.340.0x0.33-0.1x0.37-0.3x
Asset Turnover0.24-0.1x0.23-0.1x0.19-0.1x0.340.0x0.360.0x0.340.0x0.33-0.1x0.350.0x

Not reported in any period shown, so not listed: FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
MiMedx Group, Inc MDXG FY2025 $418.6M $48.6M 11.6% $445.1M 74/100
Monopar Therapeutics Inc. MNPR FY2025 $0 -$13.7M N/A $467.6M —
Shattuck Labs, Inc. STTK FY2025 $1.0M -$48.8M N/A $454.2M 61/100
Sana Biotechnology, Inc. SANA FY2025 N/A -$244.2M N/A $476.4M —
Neurogene, Inc. NGNE FY2025 $0 -$90.4M N/A $458.5M —
Assembly Biosciences, Inc ASMB FY2025 $72.3M -$6.1M -8.5% $454.4M 87/100

Frequently Asked Questions

MiMedx Group, Inc (MDXG) reported $418.6M in total revenue for fiscal year 2025. This represents a 20.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

MiMedx Group, Inc (MDXG) revenue grew by 20.0% year-over-year, from $348.9M to $418.6M in fiscal year 2025.

No, MiMedx Group, Inc (MDXG) reported a net loss of $19.2M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $48.6M, with a net profit margin of 11.6%.

MiMedx Group, Inc (MDXG) reported diluted earnings per share of $0.32 for fiscal year 2025. This represents a 14.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

MiMedx Group, Inc (MDXG) had EBITDA of $78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, MiMedx Group, Inc (MDXG) had $166.1M in cash and equivalents against $16.5M in long-term debt.

MiMedx Group, Inc (MDXG) had a gross margin of 82.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

MiMedx Group, Inc (MDXG) had an operating margin of 15.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

MiMedx Group, Inc (MDXG) had a net profit margin of 11.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

MiMedx Group, Inc (MDXG) has a return on equity of 18.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

MiMedx Group, Inc (MDXG) generated $74.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

MiMedx Group, Inc (MDXG) had $342.7M in total assets as of fiscal year 2025, including both current and long-term assets.

MiMedx Group, Inc (MDXG) invested $15.1M in research and development during fiscal year 2025.

MiMedx Group, Inc (MDXG) had 149M shares outstanding as of fiscal year 2025.

MiMedx Group, Inc (MDXG) had a current ratio of 4.32 as of fiscal year 2025, which is generally considered healthy.

MiMedx Group, Inc (MDXG) had a debt-to-equity ratio of 0.06 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

MiMedx Group, Inc (MDXG) had a liabilities-to-equity ratio of 0.34 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

MiMedx Group, Inc (MDXG) had a return on assets of 14.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

MiMedx Group, Inc (MDXG) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $445.1M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

MiMedx Group, Inc (MDXG) trades at 1.5x sales, its market capitalization divided by $303.7M revenue, trailing 12 months to September 30, 2026. The market capitalization is $445.1M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

MiMedx Group, Inc (MDXG) has an Altman Z-Score of 5.51, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

MiMedx Group, Inc (MDXG) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

MiMedx Group, Inc (MDXG) has an earnings quality ratio of 1.52x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

MiMedx Group, Inc (MDXG) has an interest coverage ratio of 35.83x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

MiMedx Group, Inc (MDXG) scores 74 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top